Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
基本信息
- 批准号:10378696
- 负责人:
- 金额:$ 99.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-15 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAddendumAddressAdverse eventAnimalsAnti-Inflammatory AgentsAntibodiesAnticoagulantsAnticoagulationAuthorization documentationBiotechnologyBloodBlood VesselsBlood coagulationBolus InfusionC-reactive proteinCause of DeathCellsChemistryChronicClinicalClinical TrialsCoagulation ProcessComplicationDataDevelopmentDevicesDialysis procedureDiseaseDoseDose-LimitingDouble-Blind MethodDrug toxicityEmergency SituationEnd stage renal failureEnzyme ActivatorsEnzymesEquipment MalfunctionEvaluationEventExposure toFibrinolytic AgentsFundingGenerationsGrantHemodialysisHemorrhageHemostatic AgentsHemostatic functionHeparinHoward Temin AwardHumanIL8 geneIncidenceIndustryInjection productInterleukin-6InterruptionIschemic StrokeKidneyLabelLeadLifeMarketingMeasurableMeasuresMedicalMiniature SwineModelingMorbidity - disease rateNo-Observed-Adverse-Effect LevelOutcome MeasurePapioPathologicPathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacologyPhasePhase II Clinical TrialsPlacebosPrimatesProceduresProtein CPublicationsPulmonary EmbolismRandomizedRecoveryRegimenRiskSafetySecureSerumSiteSmall Business Innovation Research GrantSurfaceTNF geneThrombinThromboembolismThrombolytic TherapyThrombosisThrombusTimeToxic effectVascular Graftactivated Protein Cbaseblood vessel occlusioncellular targetingclinical developmentclinically significantdesigndisabilitydrug candidatefirst-in-humanheparin-induced thrombocytopeniahuman studyimmunogenicimproved outcomeinflammatory markerinnovationmortalityneutralizing antibodypatient populationpilot trialplacebo controlled studypreclinical safetypreclinical studypreventproduct developmentresponsesafety studyside effecttargeted treatmentthrombolysisthromboticthrombotic complicationstreatment duration
项目摘要
Project Summary
Although potent antithrombotic drugs are available, all inadvertently target vital hemostatic mechanisms,
resulting in dose-limiting hemorrhagic toxicity that restricts their use. Due to a lack of safe thromboprophylaxis,
thrombotic/thromboembolic blood vessel occlusions and vascular device failures remain among the leading
causes of death and severe chronic disability in the U.S. Consequently, there is a significant and urgent unmet
medical need for safe antithrombotic drugs. The safety problem with current antithrombotics is particularly
complicated in end stage renal disease (ESRD) patients on chronic hemodialysis, who are prone to both
bleeding and thromboembolic complications. Moreover, some ESRD patients develop acute heparin induced
thrombocytopenia (HIT), another potentially life-threatening complication of heparin use in a small but
significant fraction of ESRD patients, leaving them with few if any off-label options for temporal anticoagulation
during hemodialysis sessions. We are therefore continuing clinical development of our first-in-class, FDA Fast
Track designated antithrombotic enzyme, AB002 (E-WE thrombin), by evaluating its safety and antithrombotic
activity during hemodialysis. The product candidate is a hemostatically safe antithrombotic protein C activator
enzyme that has the potential to help this desperately ill patient population. AB002 has been designed to act in
part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme,
endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This
unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling
vital hemostasis. In primates, bolus doses as low as 1 µg/kg are antithrombotic without significant systemic
anticoagulation or measurable antihemostatic effects. This critical Phase IIB Bridge Award grant will allow us to
continue product development by providing essential support for an FDA-mandated repeat dose toxicity study
and initiation of a phase 2 human clinical trial in hemodialysis patients where subjects will be repeatedly
exposed to AB002. The results from this study will be used to determine if repeated exposure to AB002 has
toxicity or elicits immunogenic responses. The animal toxicity study will be successful if there are no
observable drug toxicities. The clinical trial will be deemed successful and support further studies in this and
other indications if AB002 is not associated with clinically significant drug-related adverse events, while
showing evidence of antithrombotic and/or anti-inflammatory activity. Successfully achieving our SBIR
milestones will lead directly into the next product development stage: performing subsequent definitive trials in
hemodialysis and other clinically important thrombotic diseases (e.g. ischemic stroke, pulmonary embolism,
and acute myocardial infarction) for the benefit of patients who desperately need safer antithrombotic and
thrombolytic therapies.
项目概要
尽管有有效的抗血栓药物,但所有药物都无意中针对重要的止血机制,
导致剂量限制性出血毒性,限制其使用。由于缺乏安全的血栓预防措施,
血栓/血栓栓塞性血管闭塞和血管装置故障仍然是主要原因
美国死亡和严重慢性残疾的原因因此,存在一个重大而紧迫的未得到满足的问题
对安全抗血栓药物的医疗需求。当前抗血栓药物的安全性问题尤为突出
慢性血液透析的终末期肾病 (ESRD) 患者容易出现这两种情况
出血和血栓栓塞并发症。此外,一些 ESRD 患者会出现急性肝素诱导的
血小板减少症(HIT)是小规模但使用肝素的另一种可能危及生命的并发症
相当一部分 ESRD 患者,使他们几乎没有标签外的临时抗凝选择
在血液透析期间。因此,我们正在继续临床开发我们一流的 FDA Fast
通过评估其安全性和抗血栓作用,跟踪指定的抗血栓酶 AB002(E-WE 凝血酶)
血液透析期间的活动。该候选产品是一种止血安全的抗血栓蛋白 C 激活剂
这种酶有可能帮助这些病情危重的患者群体。 AB002 的设计目的是
部分是通过增加抗凝剂、纤溶酶和细胞保护酶的表面浓度,
内源性活化蛋白 C (APC),通过靶向细胞输送位于形成血栓的部位。这
独特的作用机制使 AB002 能够靶向富含细胞的病理性血凝块(血栓),而不会导致失能
重要的止血作用。在灵长类动物中,低至 1 µg/kg 的推注剂量即可抗血栓,且不会产生显着的全身性副作用
抗凝或可测量的抗止血作用。这项关键的 IIB 阶段桥梁奖赠款将使我们能够
通过为 FDA 规定的重复剂量毒性研究提供必要支持来继续产品开发
并启动血液透析患者的 2 期人体临床试验,受试者将重复接受
暴露于AB002。本研究的结果将用于确定重复暴露于 AB002 是否会导致
毒性或引起免疫原性反应。如果没有任何问题,动物毒性研究就会成功
可观察到的药物毒性。临床试验将被视为成功并支持这方面的进一步研究
如果 AB002 与临床上显着的药物相关不良事件无关,则有其他适应症,同时
显示出抗血栓和/或抗炎活性的证据。成功实现 SBIR
里程碑将直接进入下一个产品开发阶段:在
血液透析和其他临床上重要的血栓性疾病(例如缺血性中风、肺栓塞、
和急性心肌梗塞),以造福于迫切需要更安全的抗血栓药物和药物的患者
溶栓疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erik Ian Tucker其他文献
Erik Ian Tucker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erik Ian Tucker', 18)}}的其他基金
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10213549 - 财政年份:2019
- 资助金额:
$ 99.94万 - 项目类别:
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10616494 - 财政年份:2019
- 资助金额:
$ 99.94万 - 项目类别:
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
- 批准号:
9324070 - 财政年份:2016
- 资助金额:
$ 99.94万 - 项目类别:
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
- 批准号:
9137247 - 财政年份:2016
- 资助金额:
$ 99.94万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8641021 - 财政年份:2013
- 资助金额:
$ 99.94万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8456004 - 财政年份:2013
- 资助金额:
$ 99.94万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8826804 - 财政年份:2013
- 资助金额:
$ 99.94万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
9301688 - 财政年份:2013
- 资助金额:
$ 99.94万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 99.94万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 99.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 99.94万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 99.94万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
Operating Grants
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 99.94万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 99.94万 - 项目类别:
Partnership Projects